| 臺大學術典藏 |
2022-04-26T06:17:42Z |
Is Partial Sourcing Disadvantageous to Startup Suppliers Under Capacity-Shortage Threat?
|
Yang S.S;Chen L.; Yang S.S; Chen L.; SHU-JUNG YANG |
| 臺大學術典藏 |
2022-02-23T02:12:42Z |
Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection
|
Tai D.-I.; CHIEN-HUNG CHEN; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Chen Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Lin K.-C.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Liaw Y.-F.; Chen D.-S.; Sung J.-L. |
| 臺大學術典藏 |
2022-02-23T02:12:41Z |
Hepatitis B virus transmission and hepatocarcinogenesis: A 9 year retrospective cohort of 13 676 relatives with hepatocellular carcinoma
|
CHIEN-HUNG CHEN; Chen Y.Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Lin K.-C.; Tai D.-I.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Chen D.-S.; Liaw Y.-F.; Sung J.-L. |
| 臺大學術典藏 |
2022-02-23T02:12:38Z |
Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan
|
CHIEN-HUNG CHEN; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-23T02:12:37Z |
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan
|
Lu S.-N.; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:37Z |
Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients
|
CHIEN-HUNG CHEN; Chang T.-T.; Cheng K.-S.; Su W.-W.; Yang S.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-23T02:12:33Z |
Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: Identification of potential high HCV endemic areas
|
Su W.-W.; CHIEN-HUNG CHEN; Lin H.H.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:21Z |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; CHIEN-HUNG CHEN; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; Liu C.-J.; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-02-22T05:34:37Z |
Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection
|
Tai D.-I.; CHIEN-HUNG CHEN; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Chen Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Lin K.-C.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Liaw Y.-F.; Chen D.-S.; Sung J.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:35Z |
Hepatitis B virus transmission and hepatocarcinogenesis: A 9 year retrospective cohort of 13 676 relatives with hepatocellular carcinoma
|
CHIEN-HUNG CHEN; Chen Y.Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Lin K.-C.; Tai D.-I.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Chen D.-S.; Liaw Y.-F.; Sung J.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:32Z |
Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan
|
CHIEN-HUNG CHEN; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:31Z |
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan
|
Lu S.-N.; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:31Z |
Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients
|
CHIEN-HUNG CHEN; Chang T.-T.; Cheng K.-S.; Su W.-W.; Yang S.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:26Z |
Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: Identification of potential high HCV endemic areas
|
Su W.-W.; CHIEN-HUNG CHEN; Lin H.H.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; Sheu J.-C.; Chen D.-S.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; CHIEN-HUNG CHEN; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; Liu C.-J.; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-02-14T06:28:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; YU-JEN FANG; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:45Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:43Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; YU-JEN FANG; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; YU-JEN FANG; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.‐Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Liu C.-J.; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; YU-JEN FANG; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T05:10:44Z |
Interferon �\-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; CHI-LING CHEN; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:10:38Z |
Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus
|
Huang Y.-W.; Hu C.-Y.; CHI-LING CHEN; Liao Y.-T.; Liu C.-J.; Lai M.-Y.; Chen P.-J.; Yang S.-S.; Hu J.-T.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T05:10:34Z |
Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan
|
Huang Y.-W.; Liao Y.-T.; Chen W.; CHI-LING CHEN; Hu J.-T.; Liu C.-J.; Lai M.-Y.; Chen P.-J.; Chen D.-S.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T05:10:33Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:07:22Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; CHI-LING CHEN; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2022-01-25T03:25:19Z |
On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy
|
Huang Y.-W.; Takahashi S.; Tsuge M.; CHI-LING CHEN; Wang T.-C.; Abe H.; Hu J.-T.; Chen D.-S.; Yang S.-S.; Chayama K.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2022-01-24T09:32:16Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
CHUN-JEN LIU; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:06Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
Liu C.-H.; CHUN-JEN LIU; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:05Z |
Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus
|
Huang Y.-W.; Hu C.-Y.; Chen C.-L.; Liao Y.-T.; CHUN-JEN LIU; Lai M.-Y.; Chen P.-J.; Yang S.-S.; Hu J.-T.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:00Z |
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study
|
Chang M.-H.; You S.-L.; Chen C.-J.; CHUN-JEN LIU; Lee C.-M.; Lin S.-M.; Chu H.-C.; Wu T.-C.; Yang S.-S.; Kuo H.-S.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:59Z |
Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan
|
Huang Y.-W.; Liao Y.-T.; Chen W.; Chen C.-L.; Hu J.-T.; CHUN-JEN LIU; Lai M.-Y.; Chen P.-J.; Chen D.-S.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:59Z |
Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B
|
Huang Y.-W.; Chayama K.; Tsuge M.; Takahashi S.; Hatakeyama T.; Abe H.; Hu J.-T.; CHUN-JEN LIU; Lai M.-Y.; Chen D.-S.; Yang S.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:58Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; CHUN-JEN LIU; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:57Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; CHUN-JEN LIU; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:51Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:44Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
Liu C.-H.; Huang C.-F.; CHUN-JEN LIU; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:34Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; CHUN-JEN LIU; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:33Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; CHUN-JEN LIU; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:32Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; CHUN-JEN LIU; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:32Z |
Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study
|
Huang Y.-W.; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; CHUN-JEN LIU; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:28Z |
Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
|
Chang M.-H.; You S.-L.; Chen C.-J.; CHUN-JEN LIU; Lai M.-W.; Wu T.-C.; Wu S.-F.; Lee C.-M.; Yang S.-S.; Chu H.-C.; Wang T.-E.; Chen B.-W.; Chuang W.-L.; Soon M.-S.; Lin C.-Y.; Chiou S.-T.; Kuo H.-S.; Chen D.-S.; Yang Y.-J.; Lo G.-H.; Kong M.-S.; Wang P.-M.; Yang C.-C.; Chu C.-H.; Lin L.-H.; Chien R.-N.; Lee T.-H.; Yang K.-C.; Liao L.-Y.; Mo L.-R.; Liu J.-D.; Yang T.-H.; Lo C.-C.; Tsai M.-H.; Chou C.-H.; Cheng Y.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:18Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; CHUN-JEN LIU; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; CHUN-JEN LIU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
